IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:) Group Art Unit: 1624
) Confirmation No.: 2454
WALLACE et al.) Examiner: Noble E. Jarrell
U.S. Serial No.: 10/642,440)))
Filing Date: August 14, 2003	,)
) DATE OF TRANSMITTAL: 05/06/2009
U.S. Patent No.: 7,501,427) I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING TRANSMITTED TO THE USPTO BY ELECTRONIC FILING THROUGH PRIVATE PAIR ON THE DATE INDICATED ABOVE.
Issue Date: March 10, 2009) TYPED OR PRINTED NAME: SUSAN ELSBERRY
For: QUINAZOLINE ANALOGS AS) SIGNATURE: //Wowl 78 h
RECEPTOR TYROSINE KINASE	,
INHIBITORS)
)
Atty. File No.: 102-02-US)
Mail Stop Petition	
Director of the USPTO	
P.O. Box 1450	
Alexandria, VA 22313-1450	

REQUEST FOR RECONSIDERATION OF PATENT TERM ADJUSTMENT UNDER 37 CFR § 1.705(d)

Dear Sir:

- 1. This is a Request for Reconsideration of patent term adjustment of 695 days under 35 USC § 154(b) indicated on the above-identified patent. It is respectfully requested that Patentees be granted a minimum patent term adjustment of 1093 days.
- 2. The above-identified patent issued March 10, 2009, after payment of the issue fee on June 2, 2008. After payment of the issue fee, *Wyeth v. Dudas*, 580 F.Supp.2d 138 (D.D.C. 2008), was decided, implicating the USPTO's interpretation of 35 USC § 154. Patentee hereby requests recalculation and reconsideration of the patent term adjustment indicated in the above-identified patent in accordance with the holding in *Wyeth*.

- 3. As required by 37 CFR § 1.705(d), this request is being filed within two months of the date the patent issued and the materials required by 37 CFR § 1.705 (b)(1) and (b)(2) are included herewith.
 - 3. Patentees submit herewith a "Statement of Facts Under 37 CFR § 1.705(b)(2)".
- 4. In accordance with 37 CFR § 1.705(b)(1), please charge the fee set forth in 37 CFR § 1.18(e) (\$200) to our Deposit Account No. 50-4178.

Respectfully submitted,

ARRAY BIOPHARMA, INC., Applicant Customer Number: <u>37802</u>

By: Corev M. Williams

Registration No. 54,540

Telephone: 303-386-1340